Danaher's new project in Chongqing

 

On March 31, Danaher and Chongqing Liangjiang New Area signed a strategic cooperation agreement to build the Danaher Western Innovation Center to serve the Chengdu-Chongqing region in pharmaceutical research and innovation transformation.

 

The Danaher Western Innovation Center is located in Lijia Street in the southwest of Yubei District, adjacent to the National Regional Medical Center of Heavy Medicine Children's Hospital. The center will integrate biopharmaceutical talent training, innovation incubation, product development, customer service, technical support, application development, functional validation, collaborative office and other functions. 

 

As part of this project, Danaher will also establish a Life Sciences Research Institute here. This will be the third research institute in China for Danaher's life sciences platform, following Shanghai and Guangzhou, to serve the development of cutting-edge applications for biopharmaceuticals and precision medicine. At the same time, Cytiva, Danaher's global life sciences pioneer, will establish the Cytiva West Science and Innovation Center, which will provide biopharmaceutical process technology development, talent training, project incubation and transformation, and health economics evaluation.

Roche' first localized innovative product approved in China

 

On April 8, Roche' immunodiagnostic innovation Elecsys CA 242 was formally approved in China (BLS 20242400456). The test is the first localized innovative product that Roche Diagnostics has invested in the design and development of by integrating global resources and technologies specifically to meet the medical needs of the Chinese market, which will provide assistance in monitoring the efficacy and the whole process of management of pancreatic cancer, colorectal cancer and other malignant tumors in the digestive tract.

 

The field of oncology has always been the focus of Roche Diagnostics. In Roche's globalization layout, China has always been one of the important strategic markets. As the first localized innovative product tailored for the Chinese market, Elecsys CA 242 brings together the optimal technologies and resources of Roche Diagnostics Global (Switzerland, Germany), Roche Diagnostics Asia Pacific Production Base and R&D Center (Suzhou), and Roche Diagnostics China (Shanghai), and aims to better satisfy the local needs of Chinese patients through the whole process of design, development, production, validation, registration, and market launch of the localized product. 

Sansure's first-quarter net profit jumps nearly 20 times

On the evening of April 12, Sansure Biotech disclosed a quarterly performance forecast, during the report period, the company is expected to achieve operating income of 391 million yuan in the first quarter of 2024, an increase of 100% year-on-year; to achieve net profit of 81.489 million yuan, an increase of 36% year-on-year; after deducting non-net profit year-on-year increase of 1978%, the specific amount of 74.34 million yuan.

 

It is worth noting that the performance of Christina biological growth performance continued the trend of the fourth quarter of last year. The company's previously disclosed performance snapshot shows that in the fourth quarter of 2023, Sansure Biotech’s single-quarter revenue of 374 million yuan, a sequential growth of 83%, the first quarter of this year's revenue of 391 million yuan, once again to achieve sequential growth.

 

Respiratory products, which performed brightly last year, remain one of the key products supporting the company's performance growth.

 

In 2023, the operating income of respiratory products of Sansure Biotech exceeded 400 million yuan, with a year-on-year growth of 680%. Since this year, the high growth of this category of business continues, it is understood that its growth is driven by outpatient and emergency precision diagnosis and treatment, as well as "Internet + medical" to the home self-test demand growth. Recently, Sansure Biotech further launched DiseaseXSolution respiratory solution, aiming to meet the challenge of "Disease X" in the future through simple, efficient and intelligent prevention and control.

First time at Stanford University, Hipro opens a new chapter of heart and brain research

 

On March 19, Hipro Biotechnology' Specific Protein Analyzer was successfully deployed in Stanford Cardiovascular Institute (CVI) and successfully completed the first experiment. The experiment is based on the topic of "the effect of high prealbumin on cardiovascular disease", which is guided by Dr. Xia from Hipro American Research Center and completed by Prof. Zehra's team from Stanford Cardiovascular Institute.

 

Stanford Cardiovascular Institute is an important institution in the field of global cardiovascular research, gathering many top research talents, has been in the leading position in the field of cardiovascular research, and to help a number of local hospitals in the U.S. to conduct patient test data testing and analysis. The use of Hipro' protein immunoassay analyzer will greatly enhance the frequency of sample analysis, the ability to obtain instant results and the accuracy of data for cardiovascular research, providing strong technical support for the research team to overcome cerebrovascular diseases.